Table 3.

Association between lowering low-density lipoprotein cholesterol (LDL-C) to clinically recommended levels and CV outcomes for each subgroup.

Cohort	RA Plus General Controls RA patients, n = 1522		RA Plus OA Controls RA patients, n = 1746
Patients with RA	HR (95% CI)	p	HR (95% CI)	p
Lowered LDL-C (vs not lowered)^*	0.72 (0.49–1.07)	0.104	0.70 (0.49–1.00)	0.053
Lowered LDL-C (vs not lowered)^§	0.68 (0.46–1.02)	0.060	0.67 (0.46–0.96)	0.028
	General controls, n = 6511		OA controls, n = 2554
Non-RA patients	HR (95% CI)	p	HR (95% CI)	p
Lowered LDL-C (vs not lowered)^*	0.83 (0.63–1.09)	0.179	0.93 (0.65–1.31)	0.659
Lowered LDL-C (vs not lowered)^§	0.72 (0.55–0.95)	0.021	0.76 (0.53–1.07)	0.118

↵* Results from univariable analyses.
↵§ Results from multivariable analyses adjusting for age, sex, hypertension, antihypertensive medication use, smoking, and diabetes. CV: cardiovascular; RA: rheumatoid arthritis; OA: osteoarthritis.